ATR Enforces the Topoisomerase II-dependent G2 Checkpoint through Inhibition of Plk1 Kinase*

Received for publication, June 19, 2002, and in revised form, July 19, 2002
Published, JBC Papers in Press, July 29, 2002, DOI 10.1074/jbc.M206109200

Paula B. Deming‡§, Kristina G. Flores‡, C. Stephen Downes**, Richard S. Paules†, and William K. Kaufmann‡ ‡‡

From the ‡Department of Pathology and Laboratory Medicine, Lineberger Comprehensive Cancer Center, and Center for Environmental Health and Susceptibility, University of North Carolina, Chapel Hill, North Carolina 27599, ‡‡Growth Control and Cancer Group, NIEHS, National Institutes of Health, Research Triangle Park, North Carolina 27709, and **School of Biomedical Science, University of Ulster, Coleraine BT521SA, Northern Ireland

An ATR-dependent G2 checkpoint responds to inhibition of topoisomerase II and delays entry into mitosis by sustaining nuclear exclusion of cyclin B1-Cdk1 complexes. Here we report that induction of this checkpoint with ICRF-193, a topoisomerase II catalytic inhibitor that does not cause DNA damage, was associated with an ATR-dependent inhibition of polo-like kinase 1 (Plk1) kinase activity and a decrease in cyclin B1 phosphorylation. Expression of constitutively active Plk1 but not wild type Plk1 reversed ICRF-193-induced mitotic delay in HeLa cells, suggesting that Plk1 kinase activity is important for the checkpoint response to ICRF-193. G2/M synchronized normal human fibroblasts, when treated with ICRF-193, showed a decrease in cyclin B1 phosphorylation and Plk1 kinase activity despite high cyclin B1-Cdk1 kinase activity. G2 fibroblasts that were treated with caffeine to override the checkpoint response to ICRF-193 displayed a high incidence of chromosomal aberrations. Taken together, these results suggest that ATR-dependent inhibition of Plk1 kinase activity may be one mechanism to regulate cyclin B1 phosphorylation and sustain nuclear exclusion during the G2 checkpoint response to topoisomerase II inhibition. Moreover, the results demonstrate an important role for the topoisomerase II-dependent G2 checkpoint in the preservation of human genomic stability.

At the onset of mitosis, cyclin B1-Cdk1 kinase becomes active when the dual specificity phosphatase, Cdc25C, removes inhibitory phosphorylations on Cdk1. Once active, cyclin B1-Cdk1 complexes phosphorylate Cdc25C, which enhances its phosphatase activity. This results in an autocatalytic feedback loop and, therefore, generates a burst of cyclin B1-Cdk1 kinase activity that drives progression into mitosis. The G2 checkpoint carries out cell cycle arrest in part by inhibiting the activity of cyclin B1-Cdk1 complexes through the effector kinase Chk1. After DNA damage and replication blocks, Chk1 is phosphorylated and activated by ATR and possibly ATM (5–8). Chk1 phosphorylates Cdc25C in a 14-3-3 binding site, which causes 14-3-3 to sequester Cdc25C away from cyclin B1-Cdk1 and prevents activation of cyclin B1-Cdk1 complexes (9, 10). Initiation of the cyclin B1-Cdk1 autoamplification loop requires prior activation of Cdc25C. The kinase that first activates Cdc25C (the mitotic trigger kinase) has not been rigorously identified, although some evidence points to polo-like kinase 1 (Plk1).1

Polo-like kinases are a conserved group of protein kinases that are involved at several points in mitotic progression. They are thought to function in diverse processes such as the G2 to M cycle transition, centrosome assembly and separation, formation of the mitotic spindle, activation of the anaphase-promoting complex, and cytokinesis (11, 12). Human and Xenopus polo-like kinases (Plk1 and Plx1, respectively) have been proposed to initiate mitosis by activating Cdc25C and participating in the Cdc25C/cyclin B1-Cdk1 amplification loop (13–16). The regulation of cyclin B1-Cdk1 kinase activity during the G2 checkpoint has been suggested to occur through inhibition of Plk1 activity, which would presumably result in an inability of Cdc25C phosphatase to activate cyclin B1-Cdk1 complexes. Evidence supporting a role for regulation of Plk1 in the G2 checkpoint includes the findings that cells experiencing a DNA damage-induced mitotic delay displayed an associated decrease in Plk1 kinase activity, and overexpression of a constitutively active mutant of Plk1 reversed the mitotic delay (17). Moreover, Plk1 activity was decreased in an ATM- and/or ATR-dependent manner after treatment of cells with radiomimetic drugs and UVC, respectively (18).

Another mechanism of G2 checkpoint control independent of cyclin B1-Cdk1 activity is nuclear exclusion of cyclin B1. At the onset of mitosis, phosphorylation of cyclin B1 causes an inhibition of nuclear export and enhanced nuclear import, resulting in a net accumulation of cyclin B1-Cdk1 complexes in the nucleus (19–23). Interfering with nuclear exclusion of cyclin B1

* This work was supported in part by Public Health Service Grants CA42765 (to W. K. K.), P30-CA16086, and P30-ES10126 and a grant from the Ulster Cancer Foundation (to C. S. D.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. ¶ These authors contributed equally to this work.

‡ Supported by NIEHS, National Institutes of Health Environmental Pathology Training Grant T32-ES07017.

¶ To whom correspondence should be addressed. Tel.: 919-966-8209; Fax: 919-966-9673; E-mail: bill_kaufmann@med.unc.edu.

1 The abbreviations used are: Plk1, polo-like kinase 1; FBS, fetal bovine serum; PBS, phosphate-buffered saline; GFP, green fluorescent protein.
and down-regulation of Cdk1 kinase activity were required to significantly reverse the DNA damage G2 checkpoint in HeLa cells (23, 24). In the Xenopus system, phosphorylation of Ser-113 (analogous to Ser-147 in human cyclin B1), which resides within the cyclin B1 nuclear export sequence, interfered with the ability of the Crm1 nuclear receptor to bind to cyclin B1 and thereby inhibited nuclear export (25). Plk1 was recently shown to phosphorylate human cyclin B1 at Ser-147 and promote its thereby inhibited nuclear export (25). Plk1 was recently shown to phosphorylate Ser-147 in human cyclin B1, which resides in the G2 checkpoint may regulate the sub-cellular compartmentalization of cyclin B1-Cdk1 by controlling the phosphorylation status of cyclin B1 through inhibition of Plk1 activity.

The bisdioxopiperazinone, ICRF-193, is a topoisomerase II inhibitor that does not cause DNA damage but rather appears to block topoisomerase II at a point in its catalytic cycle after strand passage and religation but before release of the passed DNA and ATP hydrolysis (27). Therefore, ICRF-193 sequesters topoisomerase II in a "closed-clamp" conformation that tethers two DNA strands and blocks additional cycles of strand passage (27). A checkpoint is activated in G2 when topoisomerase II is inhibited with ICRF-193 (3, 4). The topoisomerase II-dependent G2 checkpoint response to ICRF-193 was recently reported to be distinct from the DNA damage G2 checkpoint as it was ATM-independent and did not appear to be enforced through inhibition of cyclin B1-Cdk1 kinase activity. Rather, it was suggested that ATR-dependent signaling acted to sustain the nuclear exclusion of cyclin B1-Cdk1 complexes (4). In this report, we show that inhibition of Plk1 kinase activity occurs in an ATR-dependent manner in cells arrested in G2 by ICRF-193. The mitotic delay response to ICRF-193 was reversed in cells expressing constitutively active Plk1 alleles, strongly suggesting that Plk1 kinase is an important element of the topoisomerase II-dependent G2 checkpoint. G2 cells arrested with ICRF-193 also displayed reduced serine phosphorylation of cyclin B1 in vivo and reduced kinase activity on cyclin B1 in cell-free extracts. Taken together these data support a model for the topoisomerase II-dependent G2 checkpoint whereby ATR signaling inhibits Plk1 activity, which in turn blocks the phosphorylation of cyclin B1 and prevents the accumulation of nuclear cyclin B1-Cdk1 complexes.

EXPERIMENTAL PROCEDURES

Cell Culture, Synchrony, Metaphase Preparation, and Transfections—NHF1-hTERT cells were maintained in minimum Eagle's medium supplemented with 10% fetal bovine serum (FBS) and 2 mM glutamine. For synchrony experiments, NHF1-hTERT cells were transfected with 0.5 μg of GFP-H2B plasmid to give a fluorescent signal to count mitotic cells. Mitotic cells were harvested or incubated with 0.01% Me2SO or 2 mM medium supplemented with 20% FBS and 2 mM L-glutamine. For transfections, cells were plated at a density of 8.0 × 103/g of total cell extract using a 4N DNA that stained positive for the mitotic epitope phospho-histone H3 antibody (Upstate Biotechnology), 5% FBS, 0.1% sodium azide, and NaCl (IFA solution) and incubated for 2 h at room temperature. Cells were then rinsed twice in IFA, resuspended in fluorescein isothiocyanate-labeled anti-mouse antibody diluted 1:20 (Santa Cruz), and incubated for 1 h at room temperature in the dark. After washes in PBS, cells were resuspended in PBS containing polyethylene glycol (PEG) (0.5% in PBS) and incubated at 37 °C for at least 30 min. For experiments with transfected HeLa cells, cells were fixed with 90% ethanol and 2.5% acetic acid in PBS for 20 min at room temperature. Cells were then rinsed with PBS, and nuclei were stained with DAPI (4',6-diamidino-2-phenylindole dihydrochloride). The fraction of mitotic cells in 2000 GFP-positive cells was determined by fluorescence microscopy.

Cyclin B1-Cdk1 Kinase Assay—Cyclin B1-associated CDK kinase activity assays were performed as previously described (4, 32).

Polo-like Kinase Activity Assay—Cells were lysed in buffer containing 50 mM Tris, pH 7.4, 1% Nonidet P-40, 250 mM NaCl, 10 mM NaF, and 5 mM EDTA and incubated on ice for 20 min. Cell lysates were clarified by centrifugation at 45,000 rpm for 20 min. Plk1 was immunoprecipitated using 1 μg of a rabbit anti-Plk1 antibody (a generous gift from Doug Ferris, National Cancer Institute, National Institutes of Health or from Upstate Biotechnology) from 300–500 μg of total protein. Samples were precleared for 30 min with protein G beads previously washed in 10× PBS and 1× kinase buffer. Samples were incubated with anti-Plk1 antibody for 2 h at 4 °C, after which 20 μl of protein G beads was added. After 30 min, samples were washed four times with kinase buffer and once in reaction buffer (20 mM HEPES, pH 7.4, 150 mM NaCl, 10 mM MgCl2, 1 mM EGTA, 0.5 mM dithiothreitol, 2.5 mM NaF, 10 mM orthovanadate). Samples were then incubated with 20 μl of kinase buffer 5 mM of phosphorylated α-casein (Sigma), and 1 μCi of [γ-32P]ATP at 34 °C for 50 min. The kinase reaction was stopped by the addition of 2× Laemmli sample buffer, and samples were subjected to SDS-PAGE (12% acrylamide gel) and autoradiography.

In Vivo Cyclin B1 Kinase Assay—Cells were lysed in kinase assay buffer containing 20 mM Tris, pH 7.5, 10 mM EGTA, 10 mM MgCl2, 0.1% Nonidet P-40, 1 mM dithiothreitol, 1 mM NaVO4, 10 mM β-glycerophosphate, 20 μg/ml aprotinin, 1 μM okadaic acid, 10 mg/ml leupeptin, 1 μM AEBSF (4-2-aminobenzyl)benzenesulfonyl fluoride; Sigma) and centrifuged at 14,000 rpm for 20 min. Cell extract (200 μg) was then incubated with 100 μl of cold ATP, 15 mM MgCl2, and 2 μl of [γ-32P]ATP for 5 min at 30 °C. Cyclin B1 was immunoprecipitated from the kinase reaction by adding 1 μg of cyclin B1 monoclonal antibody (Upstate Biotechnology) and lysis buffer and incubating for 2 h at 4 °C. Protein G beads (Sigma) were added, and samples were incubated for an additional 30 min, after which the beads were washed 4 times with kinase lysis buffer. Cyclin B1 immunoprecipitates were then subjected to SDS-PAGE (8% acrylamide gel) and autoradiography.

RESULTS

ICRF-193 Prevents Mitotic Entry and Plk1 Activation in Synchronized Human Fibroblasts—Plk1 activity levels are low in G1 and S phase but start to rise in G2 and peak in mitosis (33, 34). Because Plk1 activity is regulated by the DNA damage checkpoint and one function of Plk1 involves regulation of cyclin B1 localization, we determined whether ICRF-193-induced mitotic delay was associated with an inhibition of Plk1 activity. Normal human fibroblasts expressing telomerase (NHF1-hTERT) were synchronized to the G2 phase of the cell...
plk1 activity (analysis of matched pairs, p) displayed a significant inhibition of Plk1 activity compared to the control cells. Progression to mitosis (Fig. 1B) phase cells and significantly increased in control cells that had been previously reported a mitotic delay response to topoisomerase II inhibition with ICRF-193 despite high cyclin B1-Cdk1 kinase activity in log phase NHF1-hTERT fibroblasts and other human cell types (4), we investigated whether ICRF-193-induced inhibition of Plk1 activity was associated with an inhibition of cyclin B1 activity in synchronized cells. In synchronized NHF1-hTERT fibroblasts, cyclin B1-Cdk1 activity was low in G2 phase cells and high in mitotic cells (Fig. 1B). Cells undergoing an ICRF-193-induced mitotic delay displayed a substantial increase in cyclin B1-Cdk1 kinase activity when compared with G2-phase cells harvested 4 h earlier (Fig. 1B). Consistent with our previous report in log-phase cells (4), G2-phase fibroblasts arrested with ICRF-193 displayed only a small inhibition of cyclin B1-Cdk1 kinase activity (28%, p = 0.14) compared with the control cells allowed to accumulate in mitosis (Fig. 1B). These findings taken together with the observation of strong inhibition of Plk1 kinase activity (66%) (Fig. 1C) suggest that inhibition of Plk1 activity and cyclin B1-Cdk1 activation during the topoisomerase II-dependent G2 checkpoint response are not directly linked.

Plk1 Activity during the ICRF-193-induced Checkpoint Response Is ATR-dependent—It was recently reported that inhibition of Plk1 activity after treatment of cells with DNA-damaging agents occurs in an ATM- and ATR-dependent manner (18). Because ATR was recently shown to be the relevant kinase that enforced the topoisomerase II-dependent G2 checkpoint (4), we next investigated whether ICRF-193-induced inhibition of Plk1 activity was mediated by ATR. AT fibroblasts (GM03395) treated with ICRF-193 displayed an ICRF-193-induced inhibition of Plk1 kinase activity (57% of Me2SO controls). Taken together, these observations implied that regulation of Plk1 activity during the topoisomerase II-dependent checkpoint was ATR-dependent. To determine directly...
duced mitotic delay. To circumvent the problem of G1 arrest
constitutively active Plk1 alleles to undergo an ICRF-193-in-
tested the ability of human cells overexpressing wild type or
(17). To demonstrate directly that regulation of Plk1 activity
implied that Plk1 is a target of the DNA damage checkpoint
activation of Plk1 (17). Overexpression of these alleles in U20S
phosphorylation has been reported to result in constitutive
conserved activation loop (17). Mutation of Thr-210 (T210D) or
Plk1 (T210D or TDSD), or an empty vector plasmid (pBABE)
Myc-tagged wild type Plk1, Myc-tagged constitutively active
193-induced Checkpoint Function
entry, Plk1 activity was inhibited in an ATR-dependent man-
hibition of Plk1 activity (Fig. 2, bottom panel).

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

whether ATR mediates the ICRF-193-induced inhibition of
Plk1 activity, Plk1 kinase assays were performed in GM847
fibroblasts containing an inducible kinase-inactive ATR allele
(ATER). Treatment of non-induced GM847 fibroblasts with
ICRF-193 caused a significant inhibition in Plk1 kinase (63%
of control) (Fig. 2, bottom panel). However, cells induced to
overexpress ATER failed to display the ICRF-193-induced in-
hibition of Plk1 activity (Fig. 2, bottom panel). Like mitotic
entry, Plk1 activity was inhibited in an ATR-dependent man-
er by the topoisomerase II-dependent checkpoint response.

Overexpression of Constitutively Active Plk1 Reverses ICRF-
193-induced Checkpoint Function—Plk1 is activated by phos-
phorylation on serine and threonine residues that lie within a
conserved activation loop (17). Mutation of Thr-210 (T210D) or
both Thr-210 and Ser-137 to aspartic acid (TDSD) to mimic
phosphorylation has been reported to result in constitutive
activation of Plk1 (17). Overexpression of these alleles in U20S
cells reversed the DNA damage-induced mitotic delay, which
implied that Plk1 is a target of the DNA damage checkpoint
(17). To demonstrate directly that regulation of Plk1 activity
was required for ICRF-193-induced checkpoint function, we
test the ability of human cells overexpressing wild type or
constitutively active Plk1 alleles to undergo an ICRF-193-in-
duced mitotic delay. To circumvent the problem of G1 arrest
due to the transfection protocol in NHF1-hTERT fibroblasts,
HeLa cells lacking functional p53 were used for these experi-
ments. These HeLa cells had previously been shown to respond
to ICRF-193 with a mitotic delay similar to that seen in NHF1-
hTERT cells (4). HeLa cells were co-transfected with either
Myc-tagged wild type Plk1, Myc-tagged constitutively active
Plk1 (T210D or TDSD), or an empty vector plasmid (pBABE)
together with a GFP-histone H2B fusion protein (Fig. 3A). The
transfection efficiency was equivalent between alleles and var-
ied from 12 to 20% between experiments. This is illustrated by
the low signal of Myc-tagged Plk1 compared with the endoge-

FIG. 3. Inhibition of Plk1 activity is required for the topoi-
somerase II-dependent G2 checkpoint response. HeLa cells were
transfected with GFP-H2B together with pBABE, wtPlk1, T210D, or
TDSD plasmids, as described under “Experimental Procedures.” 48 h
after transfection, cells were incubated with Me2SO or 2 μM ICRF-193
for 2 h, then harvested for Western immunoblot analysis (A) or fixed for
mitotic index determination, which was quantified by examining GFP-
stimained nuclei using a fluorescent microscope. The results in B show the
mitotic index in ICRF-193-treated cells expressed as a percentage of the
mitotic index in the Me2SO-treated cells (mean ± S.D., n = 3).

extracts (Fig. 3A). To account for the low transfection effi-
ciency, only cells positive for GFP-H2B expression were ex-
amined for ICRF-193-induced mitotic delay. Treatment with
ICRF-193 resulted in a 49% inhibition of mitosis in GFP-H2B-
positive cells and a 40% inhibition of mitosis in GFP-H2B-
positive cells expressing the wild type Plk-1 (Fig. 3B). GFP-
H2B cells expressing the constitutively active Plk1 mutants
(T210D or TDSD) displayed no inhibition of mitosis after treat-
ment with ICRF-193 (98% of control and 105% of control,
respectively) (Fig. 3B). Thus, inhibition of Plk1 activity is re-
quired for the topoisomerase II-dependent checkpoint.

Plk1-dependent Cyclin B1 Phosphorylation Is Inhibited dur-
ing the Checkpoint Response to ICRF-193—One function of
Plk1 is to phosphorylate cyclin B1 and promote its nuclear
accumulation (26). Thus, we hypothesized that regulation of
Plk1 activity during the checkpoint response to ICRF-193 con-
trols the localization of cyclin B1-Cdk1 complexes by regulating
the phosphorylation status of cyclin B1. To test whether treat-
ment with ICRF-193 inhibits serine phosphorylation of cyclin
B1 in vivo, cyclin B1 was immunoprecipitated from synchro-
nized fibroblasts, then SDS-PAGE and immunoblots were per-
formed using antibodies to phosphoserine and cyclin B1. B, in vitro cyclin B1 phosphorylation was determined as described under “Experimental Procedures.” The autoradiograph is rep-
resentative of four independent experiments. Results show the mean
(± S.E., n = 4) increment in kinase activity relative to the G2 phase
cells.

FIG. 4. The topoisomerase II-dependent G2 checkpoint inhibits
cyclin B1 phosphorylation in vivo and in vitro. Synchronized G2
phase NHF1-hTERT fibroblasts were harvested directly or further
incubated with Me2SO or 2 μM ICRF-193 in the presence of 100 ng/ml of
Colcemid for 4 h. At the time of harvest, cells were stored as dry pellets
at −80 °C until kinase assays or immunoprecipitation immunoblots
were performed. I and M denote ICRF-193-treated and Me2SO-treated
mitotic phase cells respectively. A, cyclin B1 was immunoprecipitated
from cell lysates as described under “Experimental Procedures,” and
immunoblot analysis was performed using antibodies to phosphoserine
and cyclin B1. B, in vitro cyclin B1 phosphorylation was determined as
described under “Experimental Procedures.” The autoradiograph is rep-
resentative of four independent experiments. Results show the mean
(± S.E., n = 4) increment in kinase activity relative to the G2 phase
cells.

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z


been treated with ICRF-193, the ability of a kinase or kinases to phosphorylate endogenous cyclin B1 was significantly inhibited (27% of mitotic control) (Fig. 4B). Immunodepletion of Plk1 from mitotic cell extracts has been previously shown to abolish phosphorylation of cyclin B1 on Ser-133 and Ser-147 (26). Immunodepletion of Plk1 in extracts from Me2SO-treated mitotic NHF1-hTERT cells did not completely inhibit the phosphorylation of cyclin B1 in this system (data not shown). This result was not surprising because other kinases such as cyclin B1-Cdk1 are able to phosphorylate the first two serines within the cyclin B1 cytoplasmic retention sequence. In combination, these findings suggest that the topoisomerase II-dependent checkpoint prevents a kinase or kinases from phosphorylating serines on cyclin B1.

Bypass of the ICRF-193-induced Checkpoint with Caffeine Promotes Clastogenesis—ATR is essential for stabilization of the genome during the cell cycle, because disruption of ATR function results in the destabilization of chromosomes and cell death (4, 35). One function of ATR is to enforce the ICRF-193-induced checkpoint (4). Because the consequences of defective topoisomerase II-dependent checkpoint function have not been investigated in normal human cells, the effect of blocking ATR-dependent G2 checkpoint function in NHF1-hTERT fibroblasts was investigated. NHF1-hTERT cells were synchronized to G2 as described above. ICRF-193 or Me2SO were added to the cultures in the presence of 2 mM caffeine, a concentration known to inhibit ATR kinase activity and reverse ICRF-193-induced checkpoint function in normal human fibroblasts (36). The cells were incubated for an additional 4 h in the presence of Colcemid to capture the mitotic cells. No chromosomal aberrations were observed in 25 metaphases from mitotic control cells incubated with caffeine (Fig. 5). However, metaphases from ICRF-193-treated cells that were incubated with caffeine to bypass the checkpoint were abnormal. The chromosomes from ICRF-193-treated cells were much longer and less condensed than those from Me2SO-treated mitotic cells (Fig. 5). Moreover, 20% of the metaphases from the ICRF-193-treated cells contained chromosomes that were all unifilar, that is, the sister chromatid cores had not separated. These results are consistent with a requirement for topoisomerase II in chromatid condensation (37, 38). The remaining 80% of metaphases contained only bifilar chromosomes. Bifilar chromosomes from cells incubated with ICRF-193 in the presence of caffeine displayed aberrant structural features and frank damage (Fig. 5). All of the metaphases with bifilar chromatids exhibited constrictions or tangles between sister chromatids (Fig. 5). Fifty-six percent of the metaphases contained chromatid breaks and 60% contained exchanges. As shown in Fig. 5, some of the breaks appeared to occur at the site of a constriction.

DISCUSSION

The findings presented here demonstrate that Plk1 kinase activity and cyclin B1 phosphorylation are regulated by a topoisomerase II-dependent G2 checkpoint. Progression of synchronized human fibroblasts from G2 to M was associated with activation of Plk1, and this activation was inhibited when cells were treated with ICRF-193 to inhibit topoisomerase II catalytic activity. The regulation of Plk1 activity observed in cells experiencing an ICRF-193-induced G2 arrest was ATR-dependent because expression of a kinase-inactive ATR allele reversed the ICRF-193-induced inhibition of Plk1 kinase activity. Expression of constitutively active Plk1 mutants reversed the ICRF-193-induced mitotic delay, demonstrating that the inhibition of Plk1 kinase activity observed after treatment with ICRF-193 was not merely due to an inability of the cells to enter mitosis. This finding provides genetic evidence that inhibition of Plk1 activity is required for the topoisomerase II-dependent G2 checkpoint. Inhibition of mitosis and Plk1 activity in the presence of high cyclin B1-Cdk1 activity occurred in synchronized human fibroblasts that were treated with ICRF-193. Moreover, treatment of G2 cells with ICRF-193 also resulted in an inhibition of cyclin B1 phosphorylation. These observations support a model for the topoisomerase II-dependent G2 checkpoint whereby ATR signals to inhibit Plk1 activity, which in turn prevents the phosphorylation of cyclin B1 and, thus, sustains nuclear exclusion of cyclin B1-Cdk1 complexes (Fig. 6).

Nuclear exclusion of cyclin B1-Cdk1 complexes was previously reported to be an important component of topoisomerase II-dependent G2 checkpoint function (4). Phosphorylation at four serines within cyclin B1 is required for nuclear accumulation of cyclin B1-Cdk1 complexes at the beginning of mitosis (19–22, 25). In support of the hypothesis that one mechanism for checkpoint-enforced nuclear exclusion of cyclin B1-Cdk1 complexes is to prevent the phosphorylation of cyclin B1, serum phosphorylation of cyclin B1 was impaired in checkpoint-arrested cells. Plk1 has recently been shown to phosphorylate cyclin B1 on Ser-147 and target it to the nucleus during prophase in human cells (26). It was suggested that this phos-
phorylation event resulted in inactivation of the nuclear export sequence (26). This is consistent with the finding in the Xeno-
pus system that phosphorylation of Ser-113 resulted in the inability of cyclin B1 to bind to the Crm1a nuclear export receptor (25). Plk1 activity was inhibited in ICRF-193-treated cells, and the phosphorylation of cyclin B1 in mitotic cell extracts was diminished when Plk1 was immunodepleted from the reaction, suggesting that the ICRF-193-induced checkpoint regulates cyclin B1 localization at least in part through inhibition of Plk1 activity. Cyclin B1-Cdk1 itself has been reported to phosphorylate in vitro the first two serines within the cytoplasmic retention sequence of cyclin B1 (19, 21, 25, 39, 40). Cells arrested in G2 with ICRF-193 are able to sustain nuclear exclusion of cyclin B1-Cdk1 complexes (4) and significantly inhibit cyclin B1 phosphorylation despite high cyclin B1-Cdk1 activity. Therefore, it does not seem likely that autophosphorylation of cyclin B1 is the rate-limiting event in vivo that promotes cyclin B1 nuclear accumulation. Nevertheless, an increased amount of cyclin B1 phosphorylation was observed in ICRF-193-treated cells compared with those in G2 4 h earlier. It is possible that cyclin B1-Cdk1 autophosphorylation does occur on Ser-126 and/or Ser-128, but that nuclear accumulation requires phosphorylation of all four serines, in particular Ser-147, which inactivates the nuclear export sequence (25, 26).

Despite the finding that the activity of Plk1 kinase was significantly inhibited in G2-phase cells experiencing a topoisomerase II-dependent checkpoint response, cyclin B1-Cdk1 activity was inhibited only modestly. Therefore, it does not seem probable that the regulation of Plk1 activity mediates the activity of cyclin B1-Cdk1 during the G2 arrest induced by ICRF-193. Our data do not rule out the possibility that Plk1 initially activates the Cdc25C auto-amplification loop because there was an increase in Plk1 activity during the 4-h treatment with ICRF-193. Activation of the Cdc25C-cyclin B1-Cdk1 loop may require only a minimal amount of Plk1 activity. Inhibition of Plk1 kinase activity in the presence of substantial cyclin B1-Cdk1 activity during the ICRF-193-induced G2 arrest may be explained in part by the previous findings that neither chk1 nor chk2 is activated in cells treated with ICRF-193 (4). Without Chk1 or Chk2 activation, Cdc25C should be in an unphosphorylated state at Ser-216 (9, 10) and, therefore, capable of interacting with and activating cyclin B1-Cdk1.

Downes et al. (3) first proposed that cells express a topoisomerase II-dependent checkpoint response, cyclin B1-Cdk1 activity was inhibited only modestly. Therefore, it does not seem probable that the regulation of Plk1 activity mediates the activity of cyclin B1-Cdk1 during the G2 arrest induced by ICRF-193. Our data do not rule out the possibility that Plk1 initially activates the Cdc25C auto-amplification loop because there was an increase in Plk1 activity during the 4-h treatment with ICRF-193. Activation of the Cdc25C-cyclin B1-Cdk1 loop may require only a minimal amount of Plk1 activity. Inhibition of Plk1 kinase activity in the presence of substantial cyclin B1-Cdk1 activity during the ICRF-193-induced G2 arrest may be explained in part by the previous findings that neither chk1 nor chk2 is activated in cells treated with ICRF-193 (4). Without Chk1 or Chk2 activation, Cdc25C should be in an unphosphorylated state at Ser-216 (9, 10) and, therefore, capable of interacting with and activating cyclin B1-Cdk1.

Downes et al. (3) first proposed that cells express a topoisomerase II-dependent checkpoint that monitors the status of catenated sister chromatids after DNA replication and prevents exit from G2 until chromatids are sufficiently decat enated (3). We recently reported that unlike the DNA damage G2 checkpoint, the G2 checkpoint response to ICRF-193 was independent of ATM signaling and occurred in the absence of Chk1 and Chk2 phosphorylation and in the presence of high levels of cyclin B1-Cdk1 kinase activity (4). This study provided further evidence in support of a topoisomerase II-dependent G2 checkpoint that monitors the status of chromatid decatenation and is distinct from the DNA damage G2 checkpoint. However, although ICRF-193 does not directly generate DNA damage, it is not clear if the ICRF-193-induced closed-clamp conformation of topoisomerase II on DNA mimics a DNA lesion or interferes with DNA metabolic machinery. It is also possible that ICRF-193 affects enzymes other than topoisomerase II. Ectopic expression of the G2-specific human topoisomerase II-α in yeast sensitized cells to killing by ICRF-193 at concentrations that did not affect endogenous topoisomerase II activity (41). This result suggests that the observed effects of ICRF-193 are specifically directed at topoisomerase II and the ICRF-193-induced closed-clamp conformation of human topoisomerase II on DNA interferes with DNA metabolism (41). The signal that is gen-
erated by the closed-clamp conformation of topoisomerase II on human chromatin and which activates ATR signaling to inhibit Plk1 and delay mitosis is not known. It seems likely that the signal may be related to the presence of the tethered DNA strands that are induced by ICRF-193 or the catenated chromatids that persist when topoisomerase II function is blocked.

Overide of ICRF-193-induced G2 arrest in normal human fibroblasts using the ATR inhibitor caffeine resulted in clasto-
genesis. Metaphases from cells that bypassed the topoisomerase II-dependent checkpoint displayed chromatid breaks and exchanges as well as constrictions between daughter chromatids and tangles. ICRF-193 induced similar chromosomal aberrations in a muntjac cell line (42). The ICRF-193-induced chro mosomal aberrations are likely due to the inhibition of topoisomerase II catalytic activity producing tethered and cat enated chromatids. It is conceivable that these structures interfere with chromatin dis-cohesion producing constrictions and tangles. Torsional strain placed on the chromatids at such constriction sites by condensation forces may result in chroma tid breakage, and exchange aberrations result from erroneous repair of juxtaposed breaks. Alternatively the exchange aberrations may be the result of a recombination event targeted at sites of tethering or catenation between non-sister chromatids. Our results suggest that the checkpoint response that arrests cells in G2 when topoisomerase II catalytic activity is impaired may contribute to genetic stability by delaying mitosis until chromatid catenations have been sufficiently resolved.

The observation that inhibition of topoisomerase II catalytic activity promotes clastogenesis suggests another mechanism of genetic destabilization. The high frequency of nonreciprocal translocations recently observed in prostate cancer cell lines that were engineered to overexpress HMG1(Y) implicated a role for HMG1(Y) in DNA rearrangements (43). It was sug-
gested that because HMG1(Y) colocalizes with topoisomerase II at matrix attachment regions (MARS), the nonreciprocal translocations observed in the cells overexpressing HMG1(Y) may be a result of topoisomerase II processing of the abnormal DNA structures caused by HMG1(Y) overexpression. An alternate explanation for these results is that overexpression of HMG1(Y) interferes with the ability of topoisomerase II to decatenate DNA. Inhibition of topoisomerase II decatenatory activity in cells undergoing chromosome condensation may cause tension at the catenation sites, resulting in breaks, ille-
gitimate DNA repair, and exchange aberrations.

In conclusion, the studies presented here demonstrate a con-
nection between ATR and Plk1 that regulates entry to mitosis. It remains to be defined how ATR regulates Plk1 activity. Because Plk1 does not have any SQ sites, which are preferred ATR phosphorylation sites (44), it is unlikely that ATR regulates Plk1 directly but rather regulates either an activator or inhibitor of Plk1. Increased phosphorylation of Plk1 correlates with an increase in its activity during mitosis (33, 45); therefor e, one possibility for regulation of Plk1 during G2 checkpoint responses is the inhibition of a kinase(s) that directly phospho-
rylates Plk1. One candidate is the Ste20-like kinase, Slk1 (ho-
mologous to xPlkk1), which was recently shown to activate Plk1 during the G2 phase of the cell cycle (14, 46). Future studies should concentrate on the mechanism by which ATR regulates Plk1 activity and identify the substrate that activa tes ATR during the topoisomerase II-dependent G2 check-
point response.

Acknowledgments—We acknowledge Tim Heffernan and Drs. Dennis Simpson and Alexandra Heinloth for technical advice, Dr. Marila Cordeiro-Stone for critical reading of the manuscript, Drs. Erich Nigg (Max Planck Institute for Biochemistry) and Rene Medema (Jordan Laboratory, University Medical Center Utrecht) for providing the Plk1 plasmids, Dr. Douglas Ferris (National Cancer Institute, National In-
stitutes of Health) for antibody to Plk1, and Dr. Andrew Creighton (Medical Chemistry Laboratory, St. Bartholomew’s Hospital Medical College) for providing the ICRF-193.

REFERENCES
1. Hartwell, L. H., and Kastan, M. B. (1994) Science 266, 1821–1828
2. Kaufmann, W. K., and Paules, R. S. (1996) FASEB J. 10, 238–247
3. Downes, C. S., Clarke, D. J., Mullinger, A. M., Gimenez-Ahian, J. F., Creighton, A. M., and Johnson, R. T. (1994) Nature 372, 467–470
4. Deming, P. B., Ciutulli, C. A., Zhao, H., Graves, P. R., Piwnica-Worms, H., Paules, R. S., Downes, C. S., and Kaufmann, W. K. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 12044–12049
5. Liu, Q., Guntuku, S., Cui, X. S., Matsuoka, S., Cortez, D., Tamai, K., Luo, G., Carattini-Rivera, S., DeMayo, F., Bradley, A., Donehower, L. A., and Elledge, S. J. (2000) Genes Dev. 14, 1448–1459
6. Guo, Z., Kumagai, A., Wang, S. X., and Dunphy, W. G. (2000) Genes Dev. 14, 2745–2756
7. Dasika, G. K., Lin, S. C., Zhao, S., Sung, P., Tomkinson, A., and Lee, E. Y. (1999) Oncogene 18, 7883–7899
8. Zhao, H., and Piwnica-Worms, H. (2001) Mol. Cell. Biol. 21, 4129–4139
9. Peng, C. Y., Graves, P. R., Thoma, R. S., Wu, Z., Shaw, A. S., and Piwnica-Worms, H. (1999) Mol. Cell. Biol. 19, 5616–5624
10. Sanchez, Y., Wong, C., Thoma, R. S., Richman, R., Wu, Z., Piwnica-Worms, H., and Elledge, S. J. (1997) Science 277, 1497–1501
11. Glover, D. M., Hagan, I. M., and Tavares, A. A. (1998) Genes Dev. 12, 3777–3787
12. Nigg, E. A. (1998)Curr. Opin. Cell Biol. 10, 776–783
13. Qian, Y. W., Erikson, E., Taieb, F. E., and Muller, J. L. (2001) Mol. Cell. Biol. 21, 1791–1799
14. Qian, Y. W., Erikson, E., and Muller, J. L. (1998) Science 282, 1701–1704
15. Roshak, A. K., Capper, E. A., Imburgia, C., Fornwald, J., Scott, G., and Marshall, L. A. (2000) Cell. Signal. 12, 405–411
16. Abrieu, A., Brassac, T., Galas, S., Fisher, D., Labbe, J. C., and Duree, M. (1998) J. Cell Sci. 111, 1751–1757
17. Smits, V. A., Kompmanaker, R., Arnaud, L., Rijken, G., Nigg, E. A., and Medema, R. H. (2000) Nat. Cell Biol. 2, 672–676
18. van Vugt, M. A., Smits, V. A., Kompmanaker, R., and Medema, R. H. (2001) J. Biol. Chem. 276, 41656–41660
19. Liu, J., Meyer, A. N., and Donegoue, D. J. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 502–507
20. Haging, A., Karlsson, C., Clute, P., Jackman, M., and Pines, J. (1998) EMBO J. 17, 4125–4134
21. Haging, A., Jackman, M., Simpson, K., and Pines, J. (1999) Curr. Biol. 9, 680–689
22. Yang, J., Bardes, E. S., Moore, J. D., Brennan, J., Powers, M. A., and Kornbluth, S. (1998) Genes Dev. 12, 2131–2143
23. Toyoshima, F., Moriguchi, T., Wada, A., Fukuda, M., and Nishida, E. (1998) EMBO J. 17, 2728–2735
24. Jin, P., Hardy, S., and Morgan, D. O. (1998) J. Cell Biol. 141, 875–885
25. Yang, J., Song, H., Walsh, S., Bardes, E. S., and Kornbluth, S. (2001) J. Biol. Chem. 276, 3604–3609
26. Toyoshima-Morimoto, F., Taniguchi, E., Shinya, N., Iwamatsu, A., and Nishida, E. (2001) Nature 410, 215–220
27. Roca, J., Ishida, R., Berger, J. M., Andoh, T., and Wang, J. C. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 1781–1785
28. Kaufmann, W. K., and Wilson, S. J. (1994) Mutat. Res. 314, 67–76
29. Kaufmann, W. K., Schwartz, J. L., Hurt, J. C., Byrd, L. L., Galloway, D. A., Levedakou, E., and Paules, R. S. (1997) Cell Growth Differ. 8, 1105–1114
30. Cliby, W. A., Roberts, C. J., Cimprich, K. A., Stringer, C. M., Lamb, J. R., Schreiber, S. L., and Friend, S. H. (1998) EMBO J. 17, 159–169
31. Xu, B., Kim, S. T., and Kastan, M. B. (2001) Mol. Cell. Biol. 21, 3445–3450
32. Paules, R. S., Levedakou, E. N., Wilson, S. J., Innes, C. L., Rhodes, N., Tisty, T. D., Galloway, D. A., Donehower, L. A., Tainsky, M. A., and Kaufmann, W. K. (1995) Cancer Res. 55, 1763–1773
33. Hamanaka, R., Smith, M. R., O’Connor, P. M., Maloid, S., Mihalic, K., Srivak, J. L., Longo, D. L., and Ferris, D. K. (1995) J. Biol. Chem. 270, 21086–21091
34. Golsteyn, R. M., Mundt, K. E., Fry, A. M., and Nigg, E. A. (1995) J. Cell Biol. 129, 1617–1628
35. Brown, R. J., and Baltimore, D. (2000) Genes Dev. 14, 397–402
36. Sarkar, J. S., Bryan, E. J., Hickey, S. R., Pook, T., Taya, Y., Karnitz, L. M., and Abraham, R. T. (1999) Cancer Res. 59, 4375–4382
37. Wood, E. R., and Earnshaw, W. C. (1990) J. Cell Biol. 111, 2639–2650
38. Adachi, Y., Luke, M., and Laemmli, U. K. (1991) Cell 64, 137–148
39. Iimura, T., and Maller, J. L. (1991) Mol. Cell. Biol. 11, 3860–3867
40. Borgne, A., Ostvold, A. C., Flamant, S., and Meijer, L. (1999) J. Biol. Chem. 274, 11977–11986
41. Jensen, L. H., Nitiis, K. C., Rose, A., Dong, J., Zhou, J., Hu, T., Osheroff, N., Jensen, P. B., Sehested, M., and Nitiis, L. J. (2000) J. Biol. Chem. 275, 2137–2146
42. Gimenez-Ahian, J. F., Clarke, D. J., Devlin, J., Gimenez-Ahian, M. I., De la Torre, J., Johnson, R. T., Mullinger, A. M., and Downes, C. S. (2000) Chromosoma (Berl.) 109, 235–244
43. Takaha, N., Hawkins, A. L., Griffin, C. A., Isaacs, W. B., and Coffey, D. S. (2002) Cancer Res. 62, 647–653
44. Kim, S. T., Lim, D. S., Canman, C. E., and Kastan, M. B. (1999) J. Biol. Chem. 274, 37538–37543
45. Kelm, O., Wind, M., Lehmann, W. D., and Nigg, E. A. (2002) J. Biol. Chem. 277, 25247–25256
46. Ellinger-Ziegelbauer, H., Karamuyna, H., Yamada, E., Tsujikawa, K., Todokoro, K., and Nishida, E. (2000) Genes Cells 5, 491–498